Anyone shorting APPa right here is a FOOL with a capital "F"
The accumulation and consolidation at every move up from when I started buying it at .77 cents a share is so obvious.
this stock has never been hyped and is under the radar and has been. I agree with previous poster who observed how the MM is obviously buying for someone/some group and has tried very hard to keep stock from gapping ...
Once that buyer has gotten the shares they want ... APPA GAPS to NEW HIGH as next big move before the 18th as investors position for the 18th NEWS.
IMO
Ted
The accumulation and consolidation at every move up from when I started buying it at .77 cents a share is so obvious.
this stock has never been hyped and is under the radar and has been. I agree with previous poster who observed how the MM is obviously buying for someone/some group and has tried very hard to keep stock from gapping ...
Once that buyer has gotten the shares they want ... APPA GAPS to NEW HIGH as next big move before the 18th as investors position for the 18th NEWS.
IMO
Ted
Disclaimer: All posts are my opinion only and no one should invest without your own Due Diligence!
Recent HRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:06:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 12:30:11 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/27/2026 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:26 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 07:40:59 PM
- Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 03:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 08:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 07:49:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2026 07:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2026 06:08:24 PM
- Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth • GlobeNewswire Inc. • 01/09/2026 02:29:00 PM
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) • GlobeNewswire Inc. • 12/04/2025 01:15:00 PM
